Blocking the activin IIB receptor with bimagrumab (BYM338) increases walking performance: A meta-analysis.

Robert W SpitzScott J DankelZachary W BellVickie WongTakashi AbeMinsoo KangJeremy P Loenneke

Published in: Geriatrics & gerontology international (2021)

Our results suggest that BYM338 is a viable drug for improving 6-min walk test in populations associated with impaired function. Geriatr Gerontol Int 2021; 21: 939-943.

Keyphrases

adverse drug
genetic diversity
emergency department
binding protein